1-7 of 7
Nedjad Losic
Close
Sort by
Journal Articles

Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo , and Is Being Evaluated Clinically in Patients with B-Cell Malignancies

Ida H. Hiemstra, PhD, Patrick J. Engelberts, BS, Bart de Jong, BS, Danita H Schuurhuis, PhD, Theodora W. Salcedo, PhD DABT, Sandra Verploegen, PhD, Marten van der Zee, PhD, Arnout F. Gerritsen, PhD, Nedjad Losic, PhD, Sjeng Horbach, PhD, Roberto Oliveri, MD PhD, Jeroen J. Lammerts van Bueren, PhD, Pernille Autzen Usher, PhD, Janine Schuurman, PhD, Paul W. H. I. Parren, PhD, Esther C. W. Breij, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1664.
https://doi.org/10.1182/blood-2018-99-115957
Published: 2018
Journal Articles

Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

Xiaoyu Yan, Pamela L Clemens, Thomas Puchalski, Sagar Lonial, MD, Henk M. Lokhorst, Robert Z. Orlowski, MD PhD, Nedjad Losic, Imran Khan, Richard Jansson, Tahamtan Ahmadi, Kristen Lantz, Juan Jose Perez Ruixo, Honghui Zhou, Xu Steven Xu
Journal: Blood
Blood (2015) 126 (23): 4222.
https://doi.org/10.1182/blood.V126.23.4222.4222
Published: 2015
Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

William G. Wierda, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, PhD, Tadeusz Robak, MD, PhD, Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Richard R. Furman, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Stephan Stilgenbauer, M.D., Catherine D. Williams, FRCPath, Marek Trneny, MD, PhD, Guillaume Cartron, MD, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Swaminathan Padmanabhan, MBBS, MS, Geoffrey W. Chan, MD, Ira V. Gupta, MD, Michele M. Gorczyca, MS, Randy L. Davis, DrPH, Nedjad Losic, MSc, Steen Lisby, MD, DMSC, Anders Österborg, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 921.
https://doi.org/10.1182/blood.V116.21.921.921
Published: 2010
Journal Articles

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

Bertrand Coiffier, MD, PhD, André Bosly, MD, Ka Lung Wu, MD, PhD, Gregor Verhoef, MD, PhD, Van Eygen Koen, MD, Giovanni Martinelli, MD, Gabriela Barca, MD, PhD, Andrew Davies, MRCP, PhD, Eve Gallop-Evans, PhD, Swaminathan Padmanabhan, MBBS, MS, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Randy L. Davis, DrPH, Nedjad Losic, MSC, Steen Lisby, MD, DMSC, John A. Radford, MD
Journal: Blood
Blood (2010) 116 (21): 3955.
https://doi.org/10.1182/blood.V116.21.3955.3955
Published: 2010
Journal Articles

Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.

Anders Österborg, Birgitte Biilmann Ronn, Roxanne C Jewell, Thomas J Kipps, Jiri Mayer, Stephan Stilgenbauer, Cathy D Williams, Andrzej Hellmann, Tadeusz Robak, Richard R Furman, Peter Hillmen, Marek Trneny, Martin JS Dyer, Swami Padmanabhan, Magdalena Piotrowska, Tomas Kozak, Geoffrey Chan, Michael Arning, Nedjad Losic, Randy Davis, Joris Wilms, Charlotte A Russell, William G Wierda
Journal: Blood
Blood (2009) 114 (22): 3433.
https://doi.org/10.1182/blood.V114.22.3433.3433
Published: 2009
Journal Articles

Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial

Anders Osterborg, MD, PhD, Thomas J. Kipps, MD, PhD, Jiri Mayer, MD, Stephan Stilgenbauer, Dr.med, Catherine D Williams, MBBS, MRCP, FRCPath, Andrzej Hellmen, MD, PhD, Tadeusz Robak, MD, PhD, Richard R Furman, MD, Peter Hillmen, MBChB, PhD, Marek Trneny, MD, PhD, Martin J.S. Dyer, MA, DPhil, FRCP, Swaminathan Padmanabhan, MD, MBBS, Tomas Kozak, MD, PhD, Geoffrey Chan, MD, Randy L Davis, DrPH, Nedjad Losic, MSc, Charlotte A. Russell, MD, DMSC, Magdalena Piotrowska, MD, Joris Wilms, MSc., Pharm, William G. Wierda, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 328.
https://doi.org/10.1182/blood.V112.11.328.328
Published: 2008
Journal Articles

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

Clinical Trials & Observations
Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Flensburg, Jørgen Petersen, Nedjad Losic, John Radford
Journal: Blood
Blood (2008) 111 (12): 5486–5495.
https://doi.org/10.1182/blood-2007-10-117671
Published: 2008